Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm PR Newswire STOCKHOLM, Sept. 16, 2024 STOCKHOLM, Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas...
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM, Sept. 3, 2024 STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB...
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei PR Newswire STOCKHOLM, Sept. 3, 2024 STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- Following the...
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei PR Newswire STOCKHOLM, Sept. 3, 2024 STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- Following the...
Calliditas Interim Report January to June 2024 PR Newswire STOCKHOLM, Aug. 13, 2024 STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) : April to...
Calliditas Interim Report January to June 2024 PR Newswire STOCKHOLM, Aug. 13, 2024 STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) : April to...
Invitation to the presentation of Calliditas´s interim report January - June 2024 PR Newswire STOCKHOLM, Aug. 5, 2024 STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the...
Invitation to the presentation of Calliditas´s interim report January - June 2024 PR Newswire STOCKHOLM, Aug. 5, 2024 STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the...
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT) (“Calliditas”) Chief Executive Officer, Renée Aguiar-Lucander, will participate in a panel during this...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
